China’s BeiGene raises $175m from follow-on
Nasdaq-listed Chinese biopharmaceutical firm BeiGene has bagged $175m from a follow-on public offering of American Depositary Shares (ADSs).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: